CoChat

Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?

Open access
Tak, Young Jin, Lee, Sang Yeoup · 2021 · Current Obesity Reports

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 17 of the 177 sources its claims cite were checked for support.

Abstract

Purpose of Review As a chronic and relapsing disease, obesity impairs metabolism and causes cardiovascular diseases. Although behavioral modification is important for the treatment of obesity, it is difficult to achieve an ideal weight or sustain the process of long-term weight loss. Therefore, the obesity control guidelines strongly recommend lifestyle interventions along with medical treatment for patients who are overweight. There is sufficient evidence supporting that pharmacotherapy in combination with behavior-based interventions can result in significant weight loss and improved cardiometabolism. Recent Findings Recent meta-analyses of new anti-obesity drugs and their weight-loss efficacy have shown that the overall placebo-subtracted weight reduction (%) for at least 12 months ranged from 2.9 to 6.8% for the following drugs: phentermine/topiramate (6.8%), liraglutide (5.4%), naltrexone/bupropion (4.0%), orlistat (2.9%), and lorcaserin (3.1%). However, very recently, on February 13, 2020, the US Food and Drug Administration (FDA) ordered the withdrawal of lorcaserin from markets, as a clinical trial to assess drug safety showed an increased risk of cancer. Currently, the anti-obesity medications that have been approved by the FDA for chronic weight management are orlistat, phentermine/topiramate, naltrexone/bupropion, and liraglutide. However, they are costly and may have adverse effects in some individuals. Therefore, drug therapy should be initiated in obese individuals after weighing its benefits and risks. Summary One of the strategies for long-term obesity control is that anti-obesity medications should be tailored for specific patients depending on their chronic conditions, comorbidities, and preferences.

Overview

Integrity signals

Registry

Crossref · 10.1007/s13679-020-00422-w

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

12 Valid · 5 Not valid · 125 Not checked · 25 Own results and interpretations

65 more claims · 5 with their cited sources checked

Create a free account to see all 167 claims and to verify the 160 references still open.

See all claims — free account
  • It may state two separate claims as one. 82
  • Probably not a substantial claim. 33
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 116 references

Cited by

See all 343

Metadata

Authors
Tak, Y. J., & Lee, S. Y.
Affiliations
  • Pusan National University Hospital (KR)
  • Pusan National University Yangsan Hospital (KR)
Corresponding author
Lee, Sang Yeoup
Venue
Current Obesity Reports
Published
2021-01-06
Volume
10
Issue
1
Pages
14-30
ISSN
2162-4968 (ISSN-L)
OpenAlex
W3118501255
Cited by
343
References
116
Citations by year
2026: 36 · 2025: 67 · 2024: 69 · 2023: 72 · 2022: 56 · 2021: 42
FWCI
7.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Obesity Reports (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
anti-obesity drugs, obesity pharmacotherapy, long-term weight loss, phentermine/topiramate, liraglutide, naltrexone/bupropion, orlistat, lorcaserin, drug withdrawal, cancer risk, cardiometabolic risk, lifestyle intervention, personalized treatment, drug safety
MeSH terms
Liraglutide, Topiramate, Orlistat, Animals, Benzazepines, Humans, Naltrexone, Obesity, Phentermine, United States, United States Food and Drug Administration, Weight Loss, Bupropion, Anti-Obesity Agents, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? https://app.cochat.ai/papers/10.1007/s13679-020-00422-w
The paper
Tak, Y. J., & Lee, S. Y. (2021). Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Current Obesity Reports. https://doi.org/10.1007/s13679-020-00422-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.